Semaglutide oral bioavailability explained

Subcutaneous semaglutide reaches about 89% systemic bioavailability after injection. The oral tablet formulation of the same molecule achieves roughly 0.4% to 1% under the best conditions^[1]. A September 2026 review in Pharmaceutical Research by Vahora, Shah, and Patel maps the gap between those two numbers and asks whether formulation science can close it^[2].

The question matters because semaglutide is a peptide. Peptides are structurally fragile molecules that the gut was built to destroy, not absorb. Getting one into systemic circulation via a tablet is not a solved problem.

Why the oral bioavailability number is so low

Three barriers stack against oral semaglutide in the gastrointestinal tract. First, gastric acid and the enzyme pepsin degrade the peptide before it can be absorbed. Second, semaglutide does not cross epithelial cells readily without help: the membrane is not permeable to large, charge-bearing molecules. Third, even if intact semaglutide reaches the intestinal wall, presystemic metabolism in the gut and liver extracts a large share before it enters the bloodstream^[2].

Rybelsus, the approved oral tablet, works around these barriers using an absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate). The prescribing information specifies that SNAC raises the local pH around the tablet in the stomach, which reduces pepsin activity and limits acid-induced peptide unfolding. It also holds semaglutide in a monomeric form rather than letting it cluster into oligomers, and it promotes transcellular uptake across the gastric wall rather than relying on intestinal absorption at all

Absorption of oral semaglutide therefore happens predominantly in the stomach, not the small intestine. This is unusual for a drug and explains the strict administration rules: the tablet must be taken on an empty stomach with no more than 120 mL of water, and patients must wait at least 30 minutes before eating or drinking anything else^[3]. Food in the stomach dilutes SNAC's effect. Excess water does the same. In fed-state conditions, plasma concentrations of semaglutide fall below detection limits in some patients.

What the long half-life does for the pharmacokinetics

The pharmacokinetic variability from oral dosing is real. Patient-to-patient differences in absorption are substantial. But semaglutide's approximately one-week elimination half-life acts as a buffer: the drug builds up over four to five weeks of once-daily dosing, and steady-state exposure smooths out the day-to-day variation in absorption^[3]. The same half-life means semaglutide remains in circulation for about five weeks after the last dose, which matters clinically for patients who stop treatment or miss doses.

The Vahora et al. review notes that semaglutide's extensive albumin binding also contributes to the buffering effect: the molecule circulates largely bound to plasma protein, which limits renal clearance and extends its active presence even when absorption on a given day is lower than expected.

Formulation approaches the review examines

Current oral semaglutide (Rybelsus) uses SNAC as its sole permeation strategy. The review by Vahora et al. categorises several additional approaches under investigation. Nanotechnology-based carriers (lipid nanoparticles, polymeric nanoparticles, solid lipid carriers) aim to protect the peptide through the GI tract and deliver it to epithelial surfaces intact. Mucoadhesive formulations try to extend contact time at the absorption site. Enzyme inhibitor co-formulations pair semaglutide with agents that suppress protease activity locally^[2].

Device-based delivery, including microneedle patches applied to the buccal mucosa or small intestine, represents a different approach: bypassing the stomach entirely. Buccal patches and intestinal capsules that release drug directly onto the mucosal surface have shown feasibility in early studies, though none are approved for semaglutide specifically.

The SNAC trade-off

SNAC solved a problem that peptide chemists had been working on for decades, and it produced a commercially viable oral GLP-1 drug in Rybelsus. But its mechanism has a cost: it works gastric-first, which limits the dose that can be absorbed per tablet and requires a fasting window that patients find challenging to maintain. Suboptimal adherence to fasting conditions is likely a contributing factor to the variability seen in real-world oral semaglutide response.

What this is not

The Vahora et al. paper is a review and commentary, not a clinical trial. It does not report new bioavailability data or head-to-head comparisons between formulations. The nanotechnology and device-based approaches described are at preclinical or early clinical stages; none are approved alternatives to SNAC-enabled oral semaglutide. The 0.4% to 1% oral bioavailability figure is from the Rybelsus prescribing information and reflects the current approved formulation, not a theoretical ceiling.

The review also does not address subcutaneous semaglutide (Ozempic, Wegovy) as a comparison drug in any trial sense. For background on the full semaglutide pharmacology and regulatory status by country, that detail is on the peptide page. The question of how oral semaglutide compares to injectable options in clinical practice is covered separately under the oral semaglutide clinical guidance piece.

Where this lands

The bioavailability gap between oral and injectable semaglutide is a real limitation of the current oral formulation, not a marketing footnote. The SNAC mechanism is functional but narrow: it depends on stomach conditions, strict patient adherence, and a half-life long enough to compensate for variable daily absorption. The review by Vahora, Shah, and Patel documents where the field is and where formulation science might take it. The next generation of oral peptide delivery will need to move beyond reliance on fasting windows or accept that the injectable route retains a pharmacokinetic advantage for patients who need reliable systemic exposure.

For anyone considering oral semaglutide, the practical implication is not to stop the drug or switch formulations based on this paper. It is to take the administration instructions seriously, since variability in absorption is real and the fasting conditions are there for a pharmacological reason. Any decision about changing route of administration belongs with a clinician who knows the individual case.